Abivax Reports Share Capital and Voting Rights
Company Announcements

Abivax Reports Share Capital and Voting Rights

Abivax SA (FR:ABVX) has released an update.

Abivax, a clinical-stage biotech company, has disclosed its share capital and voting rights structure, reporting a total of 63,276,925 shares and 70,557,851 theoretical voting rights. The company, which focuses on developing treatments for chronic inflammatory diseases, has also noted that the number of exercisable voting rights stands at 70,556,237.

For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskAbivax SA Ends Liquidity Contract, Reports Cash Balance
TheFlyAbivax data support potential of obefazimod as UC treatment option
TipRanks European Auto-Generated NewsdeskAbivax Expands Trial for Potential Crohn’s Disease Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App